Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib + Digoxin in NSCLC
NCT00281021Phase 2Terminated
- Sponsor
- University of Louisville
- Start
- Feb 2006
- Primary completion
- Dec 2010
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label trial of digoxin in non-small cell lung cancer (NSCLC), sponsored by University of Louisville. Primary endpoint: Therapeutic Response at 6 weeks. Started Feb 2006; status: terminated.
02
Drugs
digoxin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00281021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281021.